PTC Therapeutics | PTCT - Equity Capital And Reserves


PTC Therapeutics reported $-180.46M in Equity Capital and Reserves for its fiscal quarter ending in March of 2026.





Equity Capital And Reserves Change Date
Acadia Pharmaceuticals USD 1.25B 20.68M Mar/2026
Alnylam Pharmaceuticals USD 1.08B 286.2M Mar/2026
Amgen USD 9.19B 532M Mar/2026
BioCryst Pharmaceuticals USD -553.84M 434.69M Mar/2026
Biogen USD 18.65B 394.9M Mar/2026
BioMarin Pharmaceutical USD 6.21B 125.11M Mar/2026
Cytokinetics USD -826.57M 166.94M Mar/2026
Daiichi Sankyo JPY 1.71T 57.86B Dec/2025
Enanta Pharmaceuticals USD 126.59M 61.87M Dec/2025
Gilead Sciences USD 23.52B 897M Mar/2026
Incyte USD 5.62B 455.37M Mar/2026
Ionis Pharmaceuticals USD 491.41M 2.32M Mar/2026
Ironwood Pharmaceuticals USD -217.14M 44.69M Mar/2026
Karyopharm Therapeutics USD -292.93M 23.67M Dec/2025
Novartis USD 38.93B 7.2B Mar/2026
Pfizer USD 90.1B 3.63B Mar/2026
PTC Therapeutics USD -180.46M 24.85M Mar/2026
Puma Biotechnology USD 115.27M 10.55M Sep/2025
Roche Holding CHF 33.8B 758M Dec/2025
Sangamo BioSciences USD 19.6M 14.7M Jun/2025
Sarepta Therapeutics USD 1.51B 364.48M Mar/2026
TG Therapeutics USD 583.13M 64.89M Mar/2026
Ultragenyx Pharmaceutical USD -236M 156M Mar/2026
Vertex Pharmaceuticals USD 19.36B 696.1M Mar/2026
Xencor USD 515.63M 119.95M Mar/2026